<WIRE> Cyclopharm (ASX:CYC) Soars on US FDA Approval, Achieving Near Three-Year High

Cyclopharm (ASX:CYC) shares experienced an 11.3% surge, elevating its market value to A$3.150 - a peak not witnessed since January 28, 2021.

The healthcare company, specializing in medical equipment and technology, announced that it has procured a coveted approval from the US Food and Drug Administration to initiate commercial sales of Technegas in America.

Technegas is a diagnostic tool used in the management of pulmonary embolism or, as it’s more colloquially known, lung artery blockage.

The company’s shares were traded 172,232 times, which is 5.4 times their average 30-day trade volume of 32,360.

An impressive performance given the company’s stock has more than doubled its value so far this year.

Cyclopharm (ASX:CYC) is a medical equipment and technology provider recognized for its revolutionary contribution in pulmonary care.

View full chart on Save $30 on a Pro or Premium TradingView account

Save $30 on a Pro or Premium TradingView account

Supported by

<SPON> Trade share CFDs with Plus500

Global online trading services company, Plus500:

Plus500 trading platform allows you to trade shares from all popular markets such as USA, UK, Germany and more, with leverage and low spreads. Using our advanced trading tools, you can also control your profits and losses.

Plus500AU Pty Ltd, AFSL #417727 issued by Australian Securities and Investments Commission. Based in Sydney.


Subscribe to the newsletter

Receive whispers every day in your inbox.